PT-141 (Bremelanotide)
price history.
One accepted seller event, the complete current exact-size market sample, and every source needed to audit the comparison.
Accepted change. Unproven trend.
This evidence is strong enough to say Pepta Labs changed this exact public row. It is not enough to say PT-141 (Bremelanotide) prices are rising across the market or that the new value will persist.
4 matching source checks
14 accepted rows share this seller and date window
2026-07-17 and 2026-07-21
A later dated snapshot is required
Two observations. One accepted change.
The previous value is Peptide Local's dated observation. The seller's current page generally cannot reproduce a superseded price.
- 2026-07-17$42.99
Previous published Pepta Labs list-price observation for the exact 10 mg row.
- 2026-07-20Candidate detected
The nightly monitor found a changed exact-size price. Publication remained blocked while the value was rechecked.
- 2026-07-21$47.29
Accepted after 4 matching source checks. Availability was recorded separately as in stock.
2 in-stock prices on one scale.
Only the same 10 mg nominal size is compared. Bars show current public list price before shipping, taxes, coupons, subscriptions, bundles, and checkout-only fees.
Price, availability, and market position stay separate.
This event can show what changed in a public listing. It cannot establish what was inside a vial or whether any research material was suitable for use.
| Vendor | Previous | Current | Change | Availability | Current market range | Source |
|---|---|---|---|---|---|---|
| Pepta Labs10 mg exact-size row | $42.992026-07-17 | $47.292026-07-21 | +$4.30+10.00% | In stock | $45.00 to $47.29$46.14 median | Seller page ↗ |
A real change, with a narrow claim.
A dated comparison of Peptide Local's previous published seller-page observation with the current public seller page. The current release contains one seller and date cluster, so its rows are not independent evidence of a market-wide trend. It is not a complete market history, transaction price, product-quality finding, or medical-product claim.
- Included: public single-unit list prices, nominal size, availability, source URL, dates, and repeated-check count.
- Excluded: shipping, taxes, coupons, subscriptions, bundles, checkout-only charges, and transaction prices.
- Not inferred: identity, purity, quantity, sterility, safety, legality, medical value, or market-wide inflation.
Direct answers, without invented history.
These answers distinguish a dated accepted event from a complete market history, transaction price, or product-quality claim.
What is the current PT-141 (Bremelanotide) 10 mg price?
Peptide Local's Jul 23, 2026 US research-market sample has 2 confirmed in-stock listings from $45.00 to $47.29, with a $46.14 median. Shipping, tax, coupons, and checkout-only fees are excluded.
How much did the tracked PT-141 (Bremelanotide) price change?
Pepta Labs's exact 10 mg public list price moved from $42.99 to $47.29, a $4.30 or 10.00% increase.
Is this a complete PT-141 (Bremelanotide) price history?
No. It is one accepted seller event between two dated Peptide Local snapshots. Earlier prices are not backfilled from search snippets, memory, or undated third-party tables.
Is PT-141 (Bremelanotide) getting more expensive?
The accepted evidence supports one narrower statement: Pepta Labs's exact 10 mg public row increased from $42.99 to $47.29. It does not yet establish that PT-141 (Bremelanotide) prices are rising across the US research market because the accepted log represents one seller and one observation window.
Was the tracked PT-141 (Bremelanotide) price increase temporary?
It is too early to classify the change as temporary or sustained. The new value passed 4 repeated source checks, but durability requires a later dated snapshot. A reversal, continued value, or similar movement at other sellers would change the interpretation.
Does a higher peptide price mean higher quality?
No. List price does not establish identity, purity, quantity, sterility, regulatory status, safety, or suitability. Seller evidence access remains a separate field.